Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Debrisoquin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | THRB | P10828 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 1/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | PHGDH | O43175 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Debrisoquin SCHEMBL29390380 | 1.00 | TMPRSS2 (1.00) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Debrisoquin SCHEMBL29711278 | 0.92 | LMNA (1.00) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Debrisoquin SCHEMBL11656689 | 0.92 | LMNA (1.00) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Debrisoquin SCHEMBL122316 | 0.92 | LMNA (1.00) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Debrisoquin SCHEMBL122317 | 0.89 | LMNA (0.83) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL17186394 | 0.86 | TMPRSS2 (0.74) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| Hydrochloric Acid SCHEMBL17186387 | 0.84 | TMPRSS2 (0.71) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL546055 | 0.81 | NOTUM (0.68) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL12420729 | 0.81 | MAOA (0.68) | TMPRSS2HTR1AADRA2ACYP2D6MAOA | |
| SCHEMBL29560844 | 0.81 | NOTUM (0.68) | TMPRSS2HTR1AADRA2ACYP2D6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1087 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| WO-2025027196-A1 | A METHOD OF PRODUCING NANOPARTICLES OF A DEFINED SIZE | IQ MEDICAL GMBH (DE) | 2025-02-06 | — | — | WO | claimed |
| WO-2025027194-A1 | A METHOD OF PREPARING AN AQUEOUS DISPERSION OF NANOPARTICLES | IQ MEDICAL GMBH (DE) | 2025-02-06 | — | — | WO | claimed |
| EP-4501320-A1 | A METHOD OF PREPARING AN AQUEOUS DISPERSION OF NANOPARTICLES | IQ medical GmbH (DE) | 2025-02-05 | — | — | EP | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| EP-0517850-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1992-12-16 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| WO-1992001385-A1 | BONING METHOD AND APPARATUS | COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESEARCH ORGANISATION (AU) | 1992-02-06 | — | — | WO | claimed |
| WO-1991012806-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | CAMPBELL JAMES N (US) | 1991-09-05 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | SLC6A2 24/4885TMPRSS2 137/4885HTR1A 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.